Intranasal 5-MeO-DMT Concomitant with SSRI for Treatment-Resistant Depression: A Proof-of-Concept Trial.
Mathieu Seynaeve, Fiona Dunbar, Chandni Hindocha, Anna O. Ermakova, Mimi Pierce, Robert R. Conley, Claire Roberts
CNS Drugs March 24, 2026 DOI: 10.1007/s40263-025-01250-z via PubMed Central
Summary
AI-generated from the abstractA proof-of-concept trial tested intranasal 5-MeO-DMT combined with an SSRI in people with treatment-resistant depression. The treatment was generally well tolerated and showed preliminary signals of antidepressant effects, though the small, uncontrolled design limits conclusions.
Study at a glance
| Characteristics | Proof-of-concept trial Peer reviewed |
|---|---|
| Population | People with treatment-resistant depression |
| Interventions | Intranasal 5-MeO-DMT SSRI |
| Key finding | Intranasal 5-MeO-DMT combined with an SSRI was well tolerated and showed preliminary antidepressant effects in treatment-resistant depression. |
Abstract
Intranasal 5-MeO-DMT Concomitant with SSRI for Treatment-Resistant Depression: A Proof-of-Concept Trial.